Innovation Management Sciences has been a strategic partner and advisor to companies, particularly with respect to intellectual property assets. These partnerships have been crucial in maximizing revenues and driving business opportunities based on innovative technologies and products. Since our inception in 2002, we have had numerous successes with over 80 public and private entities. These ventures include start-up and research universities, as well as foreign and domestic public companies.
IMSciences continues to develop activities to leverage innovation and explore collaborative business relationships.
Some examples of IMSciences activities are:
- California Institute of Technology, Pasadena, California
Website : http://www.caltech.edu
California Institute of Technology is a private research university located in Pasadena, CA and consistently ranks among the leading universities in the number of patents filed. IMSciences has invested in several ventures based on technologies developed at CalTech. These ventures were in the fields of advanced data and digital processing systems and software development.
IMSciences has a partnership with CalTech to explore opportunities for technology developed by leading professors and scientists at the university. These technology areas range from advanced rechargeable fuel cells to medical instrumentation to advanced semiconductor processing.
- Cavium Networks acquires W&W Communications, Inc., Mountain View, California
Press Release: http://www.caviumnetworks.com/newsevents_Caviumnetworks_W&W_Acquisition.html
 View PDF version
In December 2008, Cavium Networks (NASDAQ: CAVM) acquired W&W Communications, Inc., a company IMSciences had worked closely with and was a strategic investor. W&W Communications developed key technology in the area of video encoding.
- Omniture, Inc. acquires Offermatica
Press Release: http://www.omniture.com/press/384
View PDF version
Omniture, Inc (NASDAQ: QMTR), a leading provider of online business optimization software acquired privately held Offermatica, a leading on-demand and multivariate testing company. IMSciences was a key collaborator with San Francisco-based Offermatica in creating their patent portfolio, particularly in the area of rapid data processing of online data. The final acquisition cost in stock and cash was about $65 million.
- First Virtual Communications (FVC) acquired by Radvision Ltd.
Press Release: http://www.radvision.com/NR/rdonlyres/1AE56E1C-4521-4685-9592-50DC19B43C07/0/RADVISIONToPurchaseFVCAssetsfinal.pdf
View PDF version
Radvision Ltd. RVSN acquired First Virtual Communications, Inc. through court proceedings for $7.15 million. FVC was a leading provider of solutions for rich media by enabling interactive voice, video and data collaboration over IP-based networks. IMSciences played a key IP advisory role in the management, diligence and transaction process.
- PAX Scientific, Inc., San Rafael, California
Website : http://www.paxscientific.com/
Press Release: http://www.paxscientific.com/documents/PAXpressrelease--PAXStreamline.pdf
View PDF version
PAX Scientific, Inc. is a leading engineering research and product design firm that employs unique, patented design geometries to improve fluid-handling equipment, significantly reducing energy consumption. PAX Scientific recently received funding from Khosla Ventures of Menlo Park, California. PAX designs industrial equipment and other technologies that are highly efficient and innovative. PAX licenses proprietary designs to manufacturers in a variety of industries, including water treatment, wind energy, and thermal management.
"IMSciences researched candidate companies and introduced PAX Scientific to public and private potential clients including Fortune 100 companies. IMSciences helped arrange revenue-generating licensing deals involving PAX Scientific’s technologies. We found IMSciences to be enthusiastic supporters of our company mission and vision and appreciate the role that they have played in our success."
- Applied Protein Sciences
View Applied Protein Sciences Investors page
IMSciences is a key investor in Applied Protein Sciences, a Silicon Valley biopharmaceutical company focused on the prevention of Oral and GI mucositis. APS is developing proprietary proteins that help with the growth of the mucosal tissue, thereby preventing the onset of mucositis.
With APS products, patients can remain on chemotherapy or radiation for longer, which significantly increases their survival chances. In addition to mucositis, APS is expanding its drug platform to include therapeutic indications for Proctitis, Inflammatory Bowel Disease (IBD) and pain management in supportive oncology.
APS visions its products to become the defacto "Standard of Care" for supporting oncology treatments. APS has developed a strong intellectual property portfolio with nine issued US patents and an extensive international patent portfolio, protecting the technology worldwide and suitably supported with numerous pending applications.
|
